Cann Group (Cann Group) Days Payable : 0.00 (As of Dec. 2023)

View and export this data going back to 2017. Start your Free Trial

What is Cann Group Days Payable?

Cann Group's average Accounts Payable for the six months ended in Dec. 2023 was $4.84 Mil. Cann Group's Cost of Goods Sold for the six months ended in Dec. 2023 was $0.00 Mil.

The historical rank and industry rank for Cann Group's Days Payable or its related term are showing as below:

During the past 7 years, Cann Group's highest Days Payable was 54514.27. The lowest was 2241.30. And the median was 3085.68.

CNGGF's Days Payable is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 87.73
* Ranked among companies with meaningful Days Payable only.

Cann Group's Days Payable stayed the same from Dec. 2022 (0.00) to Dec. 2023 (0.00).

Cann Group Days Payable Historical Data

The historical data trend for Cann Group's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cann Group Days Payable Chart

Cann Group Annual Data

Trend

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Days Payable

Get a 7-Day Free Trial

2,266.60

3,091.76

51,864.53

Cann Group Semi-Annual Data
	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Days Payable	Get a 7-Day Free Trial									-	-	-	-	-

Competitive Comparison of Cann Group's Days Payable

For the Drug Manufacturers - Specialty & Generic subindustry, Cann Group's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cann Group's Days Payable Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cann Group's Days Payable distribution charts can be found below:

* The bar in red indicates where Cann Group's Days Payable falls into.

Cann Group Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Cann Group's Days Payable for the fiscal year that ended in Jun. 2023 is calculated as

	Days Payable (A: Jun. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Jun. 2022 )	+	Accounts Payable (A: Jun. 2023 ))	/	count )	/	Cost of Goods Sold (A: Jun. 2023 )	*	Days in Period
=	( (4.581	+	5.27)	/	2 )	/	0	*	365
=	4.9255					/	0	*	365
=	N/A

Cann Group's Days Payable for the quarter that ended in Dec. 2023 is calculated as:

	Days Payable (Q: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2023 )	+	Accounts Payable (Q: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (Q: Dec. 2023 )	*	Days in Period
=	( (5.27	+	4.41)	/	2 )	/	0	*	365 / 2
=	4.84					/	0	*	365 / 2
=	N/A

Cann Group Days Payable Related Terms

Thank you for viewing the detailed overview of Cann Group's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Cann Group (Cann Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Cann Group Ltd (OTCPK:CNGGF) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

CVJ:Germany CAN:Australia

Address

262-276 Lorimer Street, Port Melbourne, VIC, AUS, 3207

Website

https://www.canngrouplimited.com

Cann Group Ltd is engaged in the cultivation of medicinal cannabis for both medicinal and research purposes pursuant to the licenses and permits issued to the company; the development and manufacture (via third party arrangements) of finished product formulations; and the pursuit and execution of various supply and offtake agreements with third parties.